Colin F Spraggs

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. doi request reprint Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors
    Colin F Spraggs
    Genetics, Quantitative Sciences, GlaxoSmithKline Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
    Pharmacogenomics 14:541-54. 2013
  2. doi request reprint Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes
    C F Spraggs
    Genetics Department, GlaxoSmithKline Research and Development, Stevenage, UK
    Clin Pharmacol Ther 91:647-52. 2012
  3. ncbi request reprint Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar
    Colin Spraggs
    Pharmacogenetics, GlaxoSmithKline Research and Development, Harlow, Essex, UK
    Pharmacogenet Genomics 17:1065-76. 2007
  4. doi request reprint HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer
    Colin F Spraggs
    GlaxoSmithKline Research and Development, Genetics Division, Medicines Development Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NF, United Kingdom
    J Clin Oncol 29:667-73. 2011
  5. doi request reprint Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
    Chun Fang Xu
    GlaxoSmithKline Research and Development, Genetics Division, Stevenage, UK
    J Hepatol 54:1237-43. 2011
  6. doi request reprint Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
    Chun Fang Xu
    GlaxoSmithKline Medicines Research Centre, Rm 1S101, Gunnels Wood Rd, Stevenage, Hertfordshire, UK
    J Clin Oncol 29:2557-64. 2011
  7. pmc A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk
    Paul J Newcombe
    Genetics Division, GlaxoSmithKline, Stevenage, United Kingdom
    Genet Epidemiol 36:71-83. 2012
  8. ncbi request reprint Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects
    Colin F Spraggs
    Genetics Research, GlaxoSmithKline Research and Development, Medicines Research Centre, Stevenage, UK
    Pharmacogenet Genomics 15:883-9. 2005

Collaborators

Detail Information

Publications8

  1. doi request reprint Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors
    Colin F Spraggs
    Genetics, Quantitative Sciences, GlaxoSmithKline Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
    Pharmacogenomics 14:541-54. 2013
    ..The data presented demonstrate the utility of genetic studies to investigate drug-induced liver injury and potentially support its management in patients...
  2. doi request reprint Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes
    C F Spraggs
    Genetics Department, GlaxoSmithKline Research and Development, Stevenage, UK
    Clin Pharmacol Ther 91:647-52. 2012
    ....
  3. ncbi request reprint Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar
    Colin Spraggs
    Pharmacogenetics, GlaxoSmithKline Research and Development, Harlow, Essex, UK
    Pharmacogenet Genomics 17:1065-76. 2007
    ....
  4. doi request reprint HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer
    Colin F Spraggs
    GlaxoSmithKline Research and Development, Genetics Division, Medicines Development Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NF, United Kingdom
    J Clin Oncol 29:667-73. 2011
    ..This study sought to identify gene variants associated with lapatinib-induced ALT elevation and hepatobiliary AEs...
  5. doi request reprint Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
    Chun Fang Xu
    GlaxoSmithKline Research and Development, Genetics Division, Stevenage, UK
    J Hepatol 54:1237-43. 2011
    ..However, transaminase elevations have commonly been observed. This 2-stage study sought to identify genetic determinants of alanine transaminase (ALT) elevations in pazopanib-treated white patients with RCC...
  6. doi request reprint Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
    Chun Fang Xu
    GlaxoSmithKline Medicines Research Centre, Rm 1S101, Gunnels Wood Rd, Stevenage, Hertfordshire, UK
    J Clin Oncol 29:2557-64. 2011
    ..We tested the hypothesis that this variability is partially dependent on germline genetic variants that may affect pazopanib exposure or angiogenesis pathways...
  7. pmc A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk
    Paul J Newcombe
    Genetics Division, GlaxoSmithKline, Stevenage, United Kingdom
    Genet Epidemiol 36:71-83. 2012
    ..The two methods that included external information performed best, but only marginally despite substantial differences in complexity...
  8. ncbi request reprint Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects
    Colin F Spraggs
    Genetics Research, GlaxoSmithKline Research and Development, Medicines Research Centre, Stevenage, UK
    Pharmacogenet Genomics 15:883-9. 2005
    ....